Search anything
Welcome to Multibagg AI
Log in to access personalized features
Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Latest stock market news, company updates, and price movements. Stay updated with market trends, earnings insights, and investment analysis.
Gujarat Gas’ Q4FY26 beat on volumes and Ebitda comes as investors track how the GSPC-GSPL-GEL amalgamation and transmission demerger reshapes earnings and cash flows.
Shares worth ₹3.29 lakh crore (about $34 billion) across 73 newly listed firms may unlock by August 2026, raising near-term float and volatility risks.
RBI’s MPC kept the repo rate at 5.25% and reiterated a neutral stance, unveiling rupee-support measures as inflation risks rose and markets reacted positively.
India’s 10-year yield and the rupee reacted to RBI’s status quo and liquidity steps, alongside tax relief for foreign investors and falling Brent crude after a West Asia ceasefire.
RBI Governor Sanjay Malhotra said India’s forex reserves were $682.3 billion on May 29, offering about 11 months of import cover and covering 89.1% of external debt.
RBI kept the repo rate at 5.25% while lifting FY inflation projections and revising crude and rupee assumptions as West Asia conflict pushed oil prices higher.
Aurobindo Pharma shares rose 1.80% after USFDA cleared its generic Tofacitinib tablets for immediate US launch, targeting a $494 million market and adding to 586 ANDA approvals.
Paras Healthcare has refiled its DRHP with SEBI for a ₹1,800 crore IPO, combining a ₹500 crore fresh issue and a ₹1,300 crore offer for sale by promoter and investors.
RBI cut FY27 GDP growth to 6.6% from 6.9% and held the repo rate at 5.25%, citing West Asia risks, higher energy prices and supply disruptions.
India’s IPO pipeline for 2026 remains large despite a geopolitical-driven slowdown, with SEBI extending approval validity and founders facing sharper investor scrutiny on profitability and cash flows.
India is weighing a sale of up to 2% in Hindustan Zinc for about ₹5,000 crore, as Vedanta separately launches an OFS to sell 1.59%.
Alembic Pharmaceuticals has secured USFDA final approval for Haloperidol tablets across five strengths, taking its cumulative ANDA approvals to 240, including 221 final and 19 tentative.
RBI kept the repo rate at 5.25% and rolled out bond, swap and deposit measures, including wider FAR access and FCNR(B) hedging support till September 30, 2026.
Hindustan Zinc shares extended a six-session slide after a report said the government is weighing a 2% stake sale that could raise up to ₹5,000 crore.
Bharat Forge touched fresh highs as North America Class 8 net orders surged to 47,200 units, while India CV demand, defence opportunities and a premium FY27 valuation stayed in focus.
RBI kept repo at 5.25% and announced FAR expansion, relaxed NRI-OCI limits, concessional forex swaps and FCNR(B) support till Sep 30 to ease dollar liquidity.
